- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. ] Ieramilimab
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P99027 |
| Brand: | MCE |
| CAS: | - |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Ieramilimab] |
Summary
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03484923 | Novartis Pharmaceuticals|Novartis |
Melanoma
|
September 10, 2018 | Phase 2 |
| NCT02460224 | Novartis Pharmaceuticals|Novartis |
Advanced Solid Tumors
|
June 17, 2015 | Phase 1|Phase 2 |
| NCT03742349 | Novartis Pharmaceuticals|Novartis |
Triple Negative Breast Cancer (TNBC)
|
January 31, 2019 | Phase 1 |
| NCT03365791 | Novartis Pharmaceuticals|Novartis |
Small Cell Lung Cancer|Gastric Adenocarcinoma|Esophageal Adenocarcinoma|Castration Resistant Prostate Adenocarcinoma|Soft Tissue Sarcoma|Ovarian Adenocarcinoma|Advanced Well-differentiated Neuroendocrine Tumors|Diffuse Large B Cell Lymphoma
|
January 24, 2018 | Phase 2 |
| NCT03499899 | Novartis Pharmaceuticals|Novartis |
Triple-negative Breast Cancer
|
July 2, 2018 | Phase 2 |
Appearance
Liquid
Shipping
Shipping with dry ice.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.